Myriad Broadens Its Genetic Testing for Hereditary Cancers

Myriad Genetics announced last week that it would be launching a new cancer panel, called myRisk Hereditary Cancer. The panel is designed to replace Myriad’s BRACAnalysis, and represents a significant increase in diagnostic scope – whereas BRACAnalysis tested for mutations in only two genes (BRCA1 and BRCA2), the new panel will initially test for mutations in 25 genes known to influence cancer risk, and will undoubtedly grow over time.

Myriad's announcement underscores a more general shift toward understanding and treating cancer as a complex, multi-genetic disease. More importantly, it reflects a growing capacity across the industry to leverage more comprehensive genomic data to the patient’s benefit.

At GeneKey,we were founded on the belief that taking the broadest possible view of dysfunction in cancer cells will ultimately yield the most precise and actionable result. Our platform currently incorporates whole genome scans, RNA expression and copy number variation, covering more than 30,000 genes. We rapidly incorporate new technologies as they become available and are validated to remain at the cutting edge of science.

Full coverage of Myriad's announcement can be found on GenomeWeb. A free subscription is required to view the article: http://www.genomeweb.com//node/1228081